Eplontersen is an antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is available as injection for subcutaneous use. MedsAcross supplies Eplontersen for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAINUA is a transthyretin-directed antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Source: US FDA prescribing information
Eplontersen is an antisense oligonucleotide-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
Source: US FDA prescribing information
• The recommended dosage of WAINUA is 45 mg administered by subcutaneous injection once monthly. • Administer WAINUA into the abdomen or upper thigh region, the back of the upper arm can be used if a healthcare provider or caregiver administers the injection. • The prefilled syringe must be administered by a healthcare provider.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Reduced Serum Vitamin A Levels and Recommended Supplementation: Supplement with the recommended daily allowance of vitamin A. Refer to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Reduced Serum Vitamin A Levels and Recommended Supplementation. Most common adverse reactions (that occurred in at least 9% of patients treated with WAINUA) were vitamin A decreased and vomiting.
Source: US FDA prescribing information
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton protected from light. If needed, WAINUA can be kept at room temperature (up to 30°C [86°F]) in the original carton for up to 6 weeks. If not used within the 6 weeks stored at room temperature, discard WAINUA. Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Eplontersen, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Wainua 45 mg/0.8 mL injectionSubcutaneous Cold chain | AstraZeneca Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Eplontersen and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Eplontersen, including Wainua.
Yes. The US FDA first approved Eplontersen on 21 December 2023, according to Drugs@FDA.
Yes. Eplontersen has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Eplontersen must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Eplontersen is classified under ATC code N07XX21 (Eplontersen).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.